12/23/2013 4:06:06 PM
Genocea Biosciences, Inc. Files Registration Statement for Proposed Initial Public Offering
CAMBRIDGE, Mass. — Genocea Biosciences, Inc., a clinical-stage company developing novel T cell vaccines, announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to a proposed initial public offering of shares of its common stock. All shares of the common stock to be sold in the offering will be offered by Genocea Biosciences, Inc. The number of shares to be offered and the price range for the offering have not yet been determined.
Citigroup and Cowen and Company are acting as joint book-running managers for the offering. Stifel, Nicolaus & Company, Incorporated is acting as lead manager and Needham & Company, LLC is acting as co-manager.
A registration statement relating to these securities has been filed with the SEC, but has not yet become effective. These securities may not be sold and offers to buy may not be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy and there shall not be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
The offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus relating to and describing the terms of the offering may be obtained from Citigroup c/o Broadridge Financial Solutions, 1155 Long Island Ave., Edgewood, NY 11717, by calling (800) 831-9146, or by emailing firstname.lastname@example.org, or Cowen and Company c/o Broadridge Financial Services, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, by calling (631) 274-2806, or by fax (631) 254-7140.
About Genocea Biosciences, Inc.
Genocea is harnessing the power of T cell immunity to develop the next generation of vaccines. T cells are increasingly recognized as a critical element of protective immune responses to a wide range of infectious disease pathogens, but are difficult to target using traditional vaccine discovery methods. Genocea is able to identify protective T cell antigens in humans exposed to a pathogen using ATLAS™, its proprietary technology platform, potentially enabling vaccines against pathogens for which vaccine solutions do not exist or are sub-optimal. Genocea’s pipeline of novel T cell vaccines includes GEN-003 for HSV-2 therapy, GEN-004, and earlier-stage programs in chlamydia, HSV-2 prophylaxis and malaria.
Help employers find you! Check out all the jobs and post your resume.
comments powered by